This message contains images. If you don't see images, click here to view.
Click here to advertise in this news brief.




Text Version  RSS  Subscribe  Unsubscribe  Archive  Media Kit May 22, 2015
Home    About AST    Education    Meetings & Events    Public Policy    Contact Us  

 



SOCIETY NEWS

Meet your new president
AST
The AST recently announced James Allan, M.D., MBA, as president. Dr. Allan's goals for his presidency include engaging with patients and the public in support of the AST's mission, establishing new approaches to funding transplantation research, and advocating for the removal of financial disincentives to organ donation.
   Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE  




New blog post [with ATC photos]
AST
"Our society's mission is to 'advance the field of transplantation and improve patient care by promoting research, education, advocacy, and organ donation.' To this end, we have a number of exciting ongoing initiatives in these four major areas of focus.” Read more from Dr. Allan's first blog as president.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


AST Achievement Awards and Grants
AST
“This year’s award recipients are an inspiring group of transplantation professionals. They have been selected by their peers for the transformative role they have each played in shaping our field,” said AST President Dr. James Allan. “We applaud them for their dedication and success.”
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


PRODUCT SHOWCASE
 
You care about your transplant patients. And so do we. That’s why we’re introducing Astellas Cares—a new program that offers you customized tools, educational resources, and comprehensive support to help your patients care for their health. To register, visit AstellasCares.com/Transplant today.
 


Donald Hricik receives Lifetime Achievement Award
AST
The AST awarded its highest honor, the Lifetime Achievement Award, to Donald Hricik, M.D., at the recent American Transplant Congress in Philadelphia. Dr. Hricik has moved the field forward through both his involvement in clinical trials that have shaped our care of transplant patients and through his education of the next generation of transplant professionals.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


ATC 2016 Program Submission available
AST
The 2016 American Transplant Congress Program Planning Committee is now accepting program proposals for scientific sessions to be held June 11-15, 2016 in Boston, Massachusetts. Participate in the Call for Programs and share your experience and knowledge with leaders in the transplantation community from across the globe. The deadline to submit proposals is June 5, 2015.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


PRODUCT SHOWCASE
  UCLA Immunogenetics Center

The UCLA Immunogenetics Center (UIC) provides comprehensive testing for organ and tissue transplantation. Transplant testing has a long history at UCLA. HLA typing was pioneered here in the 1960's. The development of the microcytoxicity test in 1964 marked the beginning of international testing and standardization of HLA typing. The UCLA Immunogenetics Center has retained its leadership position in HLA research, and in the development of accompanying diagnostic testing. MORE
 


UPCOMING EVENTS IN TRANSPLANTATION


Education and Clinical Tools for the Independent Living Donor Advocate: A new webinar series
AST
The AST Live Donor Community of Practice announces the Education and Clinical Tools for the Independent Living Donor Advocate (ILDA) webinar series. This nine-part series starts on May 27 and runs through December, offering valuable resources for ILDAs. The entire series is free to AST members and their associates, just register with an AST member username and password at www.myAST.org/ILDA.

Non-members can purchase access to all nine webinars for just $200. Eligible non-members can join AST as a non-doctoral member and the webinar series is included in their $90 annual dues. Find out more at www.myAST.org/ILDA.

Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


PRODUCT SHOWCASE
  Missing or Broken Doppler Probes?

VTI’s disposable intraoperative Doppler probes are ready to verify technical results. There’s no longer the need to perform sterilization that frequently causes irreversible damage to the traditional Doppler probes. Advantages include fewer replacements of conventional Doppler probes damaged during sterilization, OR time saved, and a reduction in specialty procedures.
 


TRANSPLANT NEWS


A novel dual ex vivo lung perfusion technique improves immediate outcomes in an experimental model of lung transplantation
American Journal of Transplantation
The lungs are dually perfused by the pulmonary artery and the bronchial arteries. This study aimed to test the feasibility of dual-perfusion techniques with the bronchial artery circulation and pulmonary artery circulation synchronously perfused using ex vivo lung perfusion (EVLP) and evaluate the effects of dual-perfusion on posttransplant lung graft function. Using rat heart-lung blocks, we developed a dual-perfusion EVLP circuit (dual-EVLP), and compared cellular metabolism, expression of inflammatory mediators, and posttransplant graft function in lung allografts maintained with dual-EVLP, standard-EVLP, or cold static preservation.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE




ABO-identical blood group matching has no survival benefit for AB heart transplant recipients
The Annals of Thoracic Surgery via PubMed
Although identical blood group matching is preferred, it is uncertain if this results in improved survival and, if so, how large the survival benefits are. Earlier studies have yielded conflicting results and are mostly based on single-center cohorts with few long-term results. Recipients with blood group AB are of particular interest regarding nonidentical blood group matching because they may receive organs from all blood groups. We wanted to test the hypothesis that ABO-identical matching results in superior survival in recipients with blood group AB.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


COMMITMENT TO CARE
Raptor's mission is to develop and commercialize life-altering therapeutics that treat rare, debilitating, and often fatal diseases.
LEARN MORE
Advertise here!

To find out how to feature your company in the AST eNewsletter and other advertising opportunities, Contact Tom Crist at 972-402-7724.
MORE


Positive crossmatch kidney transplant recipients treated with eculizumab: Outcomes beyond 1 year
American Journal of Transplantation via PubMed
This study examined outcomes beyond 1 year in eculizumab-treated (EC) positive crossmatch kidney transplants (+XMKTx) compared to a historical control group. +XMKTx received desensitization with either plasma exchange (PE) alone (N = 48) or PE and EC (N = 30). EC, given for at least 1 month, was continued in the setting of persistently high DSA (B flow cytometric crossmatch [BFXM] greater than 200) including: 4 weeks (n = 14); 9 weeks (n = 6), 6 months (n = 2), and 12 months (n = 8).
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE




The risk of end-stage renal disease among living donor liver transplant recipients in the United States
American Journal of Transplantation
Since initiation of model for end-stage liver disease (MELD)-based allocation for liver transplantation, the risk of posttransplant end-stage renal disease (ESRD) has increased. Recent US data have demonstrated comparable, if not superior survival, among recipients of living donor liver transplants (LDLT) when compared to deceased donor liver transplant (DDLT) recipients. However, little is known about the incidence of ESRD post-LDLT.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Outbreak of influenza A(H1N1) in a kidney transplant unit—protective effect of vaccination
American Journal of Transplantation
Seasonal influenza vaccination is recommended for patients with end-stage renal disease (ESRD), despite suggested inferior efficacy among these patients. We characterize an outbreak of influenza A(H1N1) in a kidney transplant unit. Altogether 23 patients were treated on the ward for postoperative care after kidney transplantation during the outbreak. After the first positive case, all patients were tested with nasopharyngeal swab tests and 7 patients were diagnosed with influenza A(H1N1).
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


TRENDING ARTICLES
Missed last week's issue? See which articles your colleagues read most.

    Reassessing medical risk in living kidney donors (Journal of the American Society of Nephrology)
Assessing antibody strength: Comparison of MFI, C1q, and titer information (American Journal of Transplantation)
Prediction of medication non-adherence and associated outcomes in pediatric kidney transplant recipients (Pediatric Tx)
Hand and upper extremity transplantation: An update of outcomes in the worldwide experience (Plastic and Reconstructive Surgery)

Don't be left behind. Click here to see what else you missed.
 



AST eNews

Colby Horton, Vice President of Publishing, 469.420.2601
Download media kit

Julie Bernhard, Executive Editor, 469.420.2647  
Contribute news


This edition of the AST eNews was sent to ##Email##. To unsubscribe, click here.

Recent issues
May 15, 2015
May 8, 2015
May 1, 2015
April 24, 2015



Advertisement



7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063